news

August 16, 2022
GSK completes acquisition of Affinivax, Inc.
June 21, 2022
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
May 31, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
May 2, 2022
Affinivax to Highlight Preclinical Data from COVID-19 MAPS Vaccine Development Program at IMMUNOLOGY2022
February 28, 2022
Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS Platform
January 4, 2022
Affinivax to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 22, 2021
Affinivax Appoints Rick Malley, MD, as Chief Scientific Officer
December 16, 2021
Affinivax Appoints Vanya Sagar as Chief People Officer
December 13, 2021
CEPI partners with Affinivax to develop a novel COVID-19 vaccine to target variants
August 9, 2021
Affinivax Appoints Kara Bickham, MD, as Chief Medical Officer
July 12, 2021
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS Vaccine for Streptococcus pneumoniae
May 5, 2021
Affinivax Appoints Elizabeth Radcliffe as Chief Financial Officer
April 20, 2021
Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
March 9, 2021
Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS Vaccine Candidate into Clinical Trials
January 8, 2021
Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPS Vaccines Targeting Infectious Diseases
January 7, 2021
Affinivax to Present at the 39th Annual J.P. Morgan Healthcare Conference
October 21, 2020
Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS Vaccine for Streptococcus pneumoniae at IDWeek 2020
April 23, 2020
Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies
April 16, 2019
Frank Malinoski, MD, PhD, joins Affinivax as Senior Vice President of Clinical Development and Regulatory Affairs
February 13, 2019
Affinivax, Inc. announces initiation of Phase 1/2 clinical study of ASP3772, its novel pneumococcal MAPS vaccine, in collaboration with Astellas
April 3, 2018
Nosocomial Vaccine Corporation Announces Presentation on Multivalent Vaccine for Gram-Negative Pathogens, including Multiple Antibiotic-Resistant Strains at World Vaccine Conference
February 28, 2017
Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
February 5, 2016
Affinivax Secures Additional Funding to Advance its Novel Pneumococcal Vaccine towards Clinical Trials
October 26, 2015
Affinivax Announces Collaboration with ClearPath and Astellas to Develop Vaccines to Prevent Nosocomial Infections
February 12, 2015
Affinivax Announces Collaboration with PATH to Advance the Company’s Lead Vaccine Candidate for Pneumococcal Disease
October 30, 2014
Affinivax Appoints Frances K. Heller to Board of Directors
October 30, 2014
Affinivax Launches Novel Vaccine for Global Impact on Infectious Diseases
MORE

Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.

Back to Top
 

This links to an external website.

Continue